Skip to main content
Have a personal or library account? Click to login
Recent Clinical Trials Shed New Light on the Cardiovascular Benefits of Omega-3 Fatty Acids Cover

Recent Clinical Trials Shed New Light on the Cardiovascular Benefits of Omega-3 Fatty Acids

Open Access
|Jul 2019

References

  1. Kris-Etherton PM Harris WS Appel LJ American Heart Association Nutrition Committee. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease Circulation 2002 Nov 19 106 21 2747 57
  2. Siscovick DS Barringer TA Fretts AM American Heart Association Nutrition Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Epidemiology and Prevention; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; and Council on Clinical Cardiology Omega-3 Polyunsaturated Fatty Acid (Fish Oil) Supplementation and the Prevention of Clinical Cardiovascular Disease: A Science Advisory From the American Heart Association Circulation 2017 Apr 11 135 15 e867 e884
  3. Bowen KJ Harris WS Kris-Etherton PM Omega-3 Fatty Acids and Cardiovascular Disease: Are There Benefits? Curr Treat Options Cardiovasc Med. 2016 Nov 18 11 69
  4. Manson JE Cook NR Lee IM VITAL Research Group Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer N Engl J Med 2019 Jan 3 380 1 23 32
  5. Bowman L Mafham M Wallendszus K ASCEND Study Collaborative Group Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus N Engl J Med 2018 Oct 18 379 16 1540 1550
  6. Bhatt DL Steg PG Miller M REDUCE-IT Investigators Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia N Engl J Med 2019 Jan 3 380 1 11 22
  7. Bowman L Mafham M Wallendszus K ASCEND Study Collaborative Group Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus N Engl J Med 2018 Oct 18 379 16 1529 39
  8. Alexander DD Miller PE Van Elswyk ME Kuratko CN Bylsma LC A Meta-Analysis of Randomized Controlled Trials and Prospective Cohort Studies of Eicosapentaenoic and Docosahexaenoic Long-Chain Omega-3 Fatty Acids and Coronary Heart Disease Risk Mayo Clin Proc 2017 Jan 92 1 15 29
  9. Maki KC Palacios OM Bell M Toth PP Use of supplemental long-chain omega-3 fatty acids and risk for cardiac death: An updated meta-analysis and review of research gaps J Clin Lipidol. 2017 Sep - Oct 11 5 1152 1160.e2
  10. Sabatine MS Giugliano RP Keech AC FOURIER Steering Committee and Investigators Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease N Engl J Med 2017 May 4 376 18 1713 22
  11. Szarek M White HD Schwartz GG ODYSSEY OUTCOMES Committees and Investigators Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES Trial J Am Coll Cardiol 2019 Feb 5 73 4 387 96
  12. Cannon CP Blazing MA Giugliano RP IMPROVE-IT Investigators Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes N Engl J Med 2015 Jun 18 372 25 2387 97
  13. Boden WE Probstfield JL Anderson T AIM-HIGH Investigators Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy N Engl J Med 2011 Dec 15 365 24 2255 67
  14. Barter PJ Caulfield M Eriksson M ILLUMINATE Investigators Effects of torcetrapib in patients at high risk for coronary events N Engl J Med 2007 Nov 22 357 21 2109 22
  15. Bowman L Hopewell JC Chen F HPS3/TIMI55–REVEAL Collaborative Group Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease N Engl J Med 2017 Sep 28 377 13 1217 1227
  16. Lincoff AM Nicholls SJ Riesmeyer JS ACCELERATE Investigators Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease N Engl J Med 2017 May 18 376 20 1933 1942
  17. Curfman G The unfulfilled promise of omega-3 fatty acid supplementation JAMA Intern Med 2017 Feb 1 177 2 194
  18. Nicholls SJ Lincoff AM Bash D Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial Clin Cardiol 2018 Oct 41 10 1281 1288
  19. Burr ML Fehily AM Gilbert JF Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART) Lancet 1989 Sep 30 2 8666 757 61
  20. Burr ML Sweetnam PM Fehily AM Diet and reinfarction Eur Heart J 1994 Aug 15 8 1152 3
  21. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSI-Prevenzione trial Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto miocardico Lancet 1999 Aug 7 354 9177 447 55
  22. Yokoyama M Origasa H Matsuzaki M Japan EPA lipid intervention study (JELIS) Investigators Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis Lancet 2007 Mar 31 369 9567 1090 8
  23. Tavazzi L Maggioni AP Marchioli R GISSI-HF Investigators Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial Lancet 2008 Oct 4 372 9645 1223 30
  24. Kromhout D Giltay EJ Geleijnse JM Alpha Omega Trial Group N-3 fatty acids and cardiovascular events after myocardial infarction N Engl J Med 2010 Nov 18 363 21 2015 26
  25. Rauch B Schiele R Schneider S OMEGA Study Group OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction Circulation 2010 Nov 23 122 21 2152 9
  26. Galan P Kesse-Guyot E Czernichow S Briancon S Blacher J Hercberg S SU.FOL.OM3 Collaborative Group Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial BMJ 2010 Nov 29 341 c6273
  27. ORIGIN Trial Investigators Bosch J Gerstein HC n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia N Engl J Med 2012 Jul 26 367 4 309 18
  28. Risk and Prevention Study Collaborative Group Roncaglioni MC Tombesi M n-3 fatty acids in patients with multiple cardiovascular risk factors N Engl J Med 2013 May 9 368 19 1800 8
  29. Rischio and Prevenzione Investigators Efficacy of n-3 polyunsaturated fatty acids and feasibility of optimizing preventive strategies in patients at high cardiovascular risk: Rationale, design and baseline characteristics of the Rischio and Prevenzione study, a large randomised trial in general practice Trials 2010 May 28 11 68
  30. Writing Group for the AREDS2 Research Group Bonds DE Harrington M Effect of long-chain ω-3 fatty acids and lutein + zeaxanthin supplements on cardiovascular outcomes: results of the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial JAMA Intern Med 2014 May 174 5 763 71
  31. Jacobson TA Role of n-3 fatty acids in the treatment of hypertriglyceridemia and cardiovascular disease Am J Clin Nutr 2008 Jun 87 6 1981S 90S
  32. Skulas-Ray AC West SG Davidson MH Kris-Etherton PM Omega-3 fatty acid concentrates in the treatment of moderate hypertriglyceridemia Expert Opin Pharmacother 2008 May 9 7 1237 48
  33. Davidson MH Stein EA Bays HE COMBination of prescription Omega-3 with Simvastatin (COMBOS) Investigators Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study Clin Ther 2007 Jul 29 7 1354 67
  34. Ballantyne CM Bays HE Kastelein JJ Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study) Am J Cardiol 2012 Oct 1 110 7 984 92
  35. Oh PC Koh KK Sakuma I Omega-3 fatty acid therapy dose-dependently and significantly decreased triglycerides and improved flow-mediated dilation, however, did not significantly improve insulin sensitivity in patients with hypertriglyceridemia Int J Cardiol 2014 Oct 20 176 3 696 702
  36. Maki KC Orloff DG Nicholls SJ A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial) Clin Ther 2013 Sep 35 9 1400 11.e1-3
  37. Skulas-Ray AC Kris-Etherton PM Harris WS Vanden Heuvel JP Wagner PR West SG Dose-response effects of omega-3 fatty acids on triglycerides, inflammation, and endothelial function in healthy persons with moderate hypertriglyceridemia Am J Clin Nutr 2011 Feb 93 2 243 52
  38. Mozaffarian D Wu JH (n-3) fatty acids and cardiovascular health: are effects of EPA and DHA shared or complementary? J Nutr. 2012 Mar 142 3 614S 625S
  39. Calder PC Omega-3 fatty acids and inflammatory processes: from molecules to man Biochem Soc Trans 2017 Oct 15 45 5 1105 1115
  40. Rosenthal MD Patel J Staton K Martindale RG Moore FA Upchurch GR Jr. Can Specialized Pro-resolving Mediators Deliver Benefit Originally Expected from Fish Oil? Curr Gastroenterol Rep. 2018 Aug 4 20 9 40
  41. Endo J Sano M Isobe Y 18-HEPE, an n-3 fatty acid metabolite released by macrophages, prevents pressure overload-induced maladaptive cardiac remodeling J Exp Med 2014 Jul 28 211 8 1673 87
  42. Richter CK Skulas-Ray AC Kris-Etherton P Recommended intake of fish and fish oils worldwide In Raatz S Bibus DM editors Fish and fish oils in health and disease San Diego Academic Press 2016 p 27 48
  43. Thompson M Hein N Hanson C Omega-3 Fatty Acid Intake by Age, Gender, and Pregnancy Status in the United States: National Health and Nutrition Examination Survey 2003–2014 Nutrients 2019 Jan 15 11 1
  44. Richter CK Bowen KJ Mozaffarian D Kris-Etherton PM Skulas-Ray AC Total Long-Chain n-3 Fatty Acid Intake and Food Sources in the United States Compared to Recommended Intakes: NHANES 2003–2008 Lipids 2017 Nov 52 11 917 927
  45. Jackson KH Polreis JM Tintle NL Kris-Etherton PM Harris WS Association of reported fish intake and supplementation status with the omega-3 index Prostaglandins Leukot Essent Fatty Acids 2019 Mar 142 4 10
  46. Harris WS Von Schacky C The Omega-3 Index: a new risk factor for death from coronary heart disease? Prev Med. 2004 Jul 39 1 212 20
  47. Del Gobbo LC Imamura F Aslibekyan S Omega-3 polyunsaturated fatty acid biomarkers and coronary heart disease: Pooling project of 19 cohort studies JAMA Intern Med 2016 Aug 1 176 8 1155 66
  48. Harris WS Tintle NL Etherton MR Vasan RS Erythrocyte long-chain omega-3 fatty acid levels are inversely associated with mortality and with incident cardiovascular disease: The Framingham Heart Study J Clin Lipidol. 2018 May - Jun 12 3 718 727.e6
  49. Rimm EB Appel LJ Chiuve SE American Heart Association Nutrition Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Epidemiology and Prevention; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; and Council on Clinical Cardiology Seafood Long-Chain n-3 Polyunsaturated Fatty Acids and Cardiovascular Disease: A Science Advisory From the American Heart Association Circulation 2018 Jul 3 138 1 e35 e47
Language: English
Page range: 171 - 178
Published on: Jul 1, 2019
Published by: Houston Methodist DeBakey Heart & Vascular Center
In partnership with: Paradigm Publishing Services

© 2019 Penny M. Kris-Etherton, Chesney K. Richter, Kate J. Bowen, Ann C. Skulas-Ray, Kristina Harris Jackson, Kristina S. Petersen, William S. Harris, published by Houston Methodist DeBakey Heart & Vascular Center
This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 License.